View the EURETINA 2022 symposium on Advancing the management of nAMD: Latest clinical insights from targeting Ang-2/VEGF-A via dual inhibition

Targeting additional pathways beyond vascular endothelial growth factor A (VEGF-A) may address treatment challenges in neovascular age-related macular degeneration (nAMD) and optimise patient outcomes. In particular, the Angiopoietin (Ang)-Tie pathway shows promise as a novel therapeutic target to address the vascular instability observed in retinal diseases. This symposium will summarise the impact of dual Ang-2/VEGF-A inhibition, highlight the opportunities to improve clinical outcomes in nAMD, outline preclinical evidence and clinical findings for dual Ang-2/VEGF-A inhibition, and review patient cases for faricimab▼ in the clinic and the real-world.